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Abstract 
Background: Mesenchymal stem cell (MSC) has been widely explored in the past decade as a cell-based treatment 
for various diseases. However, poor survival of adaptively transferred MSCs limits their clinical therapeutic potentials, 
which is largely ascribed to the nutrient starvation. In this study, we determined whether a novel kidney protective 
peptide CHBP could protect MSCs against starvation and invested the underlying mechanisms.
Methods: MSCs were subjected to serum deprivation and CHBP of graded concentrations was administered. Cell 
viability and apoptosis were detected by CCK-8, Annexin V/PI assay and Hoechst staining. ROS generation, mitochon-
drial membrane potential indicated by JC-1 and mitochondrial mass were measured by flow cytometry. The location 
of cytochrome c within cells was observed under fluorescence microscopy. Expressions of Nrf2, Sirt3, and FoxO3a were 
analyzed by western blot. In addition, preconditioning MSCs with CHBP was applied to test the possible protection 
against starvation. Finally, the effect of CHBP on the differentiation and self-renewal capacity of MSCs was also examined.
Results: CHBP improved cell viability and suppressed apoptosis in a dose dependent manner. Starvation resulted 
in the mitochondrial dysfunction and treatment of CHBP could alleviate mitochondrial stress by diminishing oxida-
tive injury of ROS, restoring mitochondrial membrane potential and maintaining mitochondrial membrane integrity. 
Importantly, Nrf2/Sirt3/FoxO3a pathway was activated by CHBP and Sirt3 knockdown partially abolished the protec-
tion of CHBP. Moreover, MSCs pretreated with CHBP were more resistant to starvation. Under normal condition, CHBP 
exerted little effects on the differential and self-renewal capacity of MSCs.
Conclusions: The present study demonstrated the efficient protection of CHBP upon MSCs against starvation-
induced mitochondrial dysfunction and apoptosis and indicated possible involvement of Nrf2/Sirt3/FoxO3a pathway 
in the protective effect.
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Background
Mesenchymal stem cell (MSC) is a common adult stem 
cell originating from the mesoderm and characterized by 
its multi-potentiality and unique immune-modulatory 
property [1, 2]. Besides their classic tri-lineage differen-
tiation into adipocytes, osteoblasts, and chondrocytes, 
it is reported that MSCs can also differentiate into ecto-
dermal and endodermal cells, such as endothelial cells, 
smooth muscle cells, hepatocytes, and cardiomyocytes 
[3, 4]. Importantly, as adult stem cells, MSCs can be 
easily isolated and feasibly expanded ex vivo [5]. In this 
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An increasing body of evidence has demonstrated 
that MSCs hold great promise for the therapy of tis-
sue injuries, inflammatory diseases, and allograft rejec-
tions [6–12]. However, in most cases the survival rate of 
adoptively transferred MSCs is poor, which significantly 
hampers the treatment efficiency [13–15]. Although 
the therapeutic capability of MSCs, in the settings of 
some diseases, might rely on regulating inflammation 
and enhancing endogenous tissue repair [16, 17], longer 
survival and retention time would optimize MSC-based 
therapy efficacies. The reason that transplanted MSCs 
are short-lived could be largely ascribed to the complex 
microenvironments. After adoptive transfer, MSCs will 
encounter with various undesirable factors including 
nutrient deprivation, oxidative stress, inflammation reac-
tions and so on, all of which could decrease the cell via-
bility and thereby compromise their therapeutic activities 
[18–21]. Nutrient starvation is one of the major obstacles 
confronted by engrafted MSCs, especially within injured 
tissues. In spite that appropriate preconditioning with 
hypoxia and serum starvation could augment the cellular 
viability, prolonged exposure to starvation will be a lethal 
disaster for MSCs [22, 23]. Therefore, improving survival 
of MSCs under starvation conditions is of vital impor-
tance for the MSC-based cell therapies.
Cyclic helix B peptide (CHBP) is a novel erythropoie-
tin-derived peptide synthesized by our group recently 
with prominent renoprotective effect [24–27]. Our previ-
ous studies have demonstrated that CHBP could alleviate 
kidney ischemia–reperfusion injury through inhibiting 
apoptosis as well as inflammatory responses [25, 26]. 
However, whether CHBP is able to exert cytoprotection 
in the background of starvation remains elusive. In the 
present study, we adopted the serum deprivation strategy 
to mimic the starvation during MSCs’ administration. 
Treatment of CHBP significantly improved mitochon-
drial dysfunction, prevented apoptosis and prolonged cell 
survival. Moreover, we revealed that CHBP exerted its 
cytoprotection through Nrf2/Sirt3/FoxO3a pathway. This 
research provided a novel pharmacological recognition of 
CHBP for the cytoprotective effects and suggested CHBP 
as a promising adjuvant agent in cell-based treatments.
Methods
Cell culture and treatment
Primary bone marrow-derived MSCs of C57/BL6 mice 
were purchased from Cyagen Biosciences Inc. (Guang-
zhou, China). MSCs were cultured in Dulbecco’s modi-
fied Eagle’s medium/F12 (DMEM/F12) medium with 
10% heat-inactivated fetal bovine serum, 2 mmol/L glu-
tamine, 100 U/ml penicillin, and 100 mg/ml streptomy-
cin at 37 °C in a humidified incubator containing 5% CO2. 
All experiments were performed on MSCs from 6th to 
10th passages. Apoptosis was induced by serum depriva-
tion. Briefly, after MSCs were seeded into 6-well plates 
or 96-well plates, the culture medium was replaced with 
serum-free DMEM low glucose with or without CHBP at 
various concentrations (0.1, 1, 10 nmol/L). MSCs main-
tained in complete medium were used as the normal 
control. To exclude a nonspecific impact of peptide itself, 
a scrambled control peptide (LSEARNQSEL) was also 
used. Both CHBP and scrambled peptide were dissolved 
in PBS.
Cell viability
Cell viability in response to starvation was examined 
by Cell Counting Kit-8 (CCK-8, Dojindo, Shanghai, 
China). Cells were seeded in 96-well plates at a density 
of 1  ×  104  cells/well. After different treatment, 10ul of 
CCK-8 reagent was added to each well of the 96-well 
plates and incubated at 37 °C for 2 h. The absorbance of 
each sample at 450  nm was measured by a microplate 
reader.
Meanwhile, trypan blue staining was used to dis-
tinguish cell death. MSCs were seeded in 6-well 
plates  1  ×  106  cells/well cells and treated differently. 
Then non-adherent and adherent cells were harvested 
and resuspended in 1 ml complete medium. 5 μl of these 
cell suspensions were aspirated and mixed with an equal 
volume of 0.4% trypan blue solution, and finally counted 
using a hemacytometer under microscope.
Annexin V/PI assay
To further explore the protection of CHBP against star-
vation, cell death was analyzed using Annexin V–FITC/
PI apoptosis detection kit (Vazyme Biotech, Nanjing, 
China). According to the manufacturer’s protocol, cells 
were harvested and resuspended in 100 μl binding buffer 
mixed with 5 μl Annexin V-FITC reagent and 5 μl PI rea-
gent. After incubation for 15 min at room temperature in 
the dark, another 400  μl binding buffer was added, and 
cells were measured by flow cytometry (Beckman Coul-
ter). Data was analyzed with FlowJo software.
Hoechst staining
Hoechst 33258 (Beyotime, Nanjing, China) was used 
for to examine the morphological changes of apoptosis. 
MSCs with different treatment were fixed in 4% para-
formaldehyde for 2  h and subsequently stained with 
Hoechst 33258 reagent for 30 min at room temperature. 
Nuclear alterations were then observed under fluores-
cence microscopy. Fragmentation and condensation 
of the nucleus were recognized as the characteristics of 
apoptotic cells.
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Reactive oxygen species (ROS), mitochondrial membrane 
potential (MMP), and mitochondrial mass detection
Briefly, for quantitative detection of mitochondria-
derived ROS, MMP and mitochondrial mass, cells were 
incubated with MitoSOX reagent (2.5  mmol/L, Invitro-
gen), JC-1 reagent (5  mg/mL, Beyotime), and MitoRed 
(50 nmol/L, KeyGEN Biotech) for 30 min at 37 °C. Subse-
quently, MSCs were collected, washed with PBS and then 
analyzed by flow cytometry.
Immunofluorescence staining
Cells were first incubated with 50  nmol/L MitoRed for 
30 min at 37 °C. To examine cytochrome c location, cells 
were fixed in 4% paraformaldehyde for 2  h, permeabi-
lized with 0.2% Triton X-100 for 5  min. After blocked 
with 10% bovine serum albumin for 1 h at room tempera-
ture, cells were incubated with primary antibody against 
cytochrome c (1:500, Beyotime) overnight at 4  °C, and 
subsequently incubated with FITC-conjugated secondary 
antibodies (1:1000, Beyotime). Locations of mitochon-
dria and cytochrome c were visualized under fluores-
cence microscopy.
Knockdown of Sirt3 by small interfering RNA (siRNA)
For knockdown of Sirt3 in  vitro, siRNA targeting Sirt3 
(ThermoFisher Scientific, AM16708) was used. The 
siRNA was transfected into MSCs using Lipofectamine 
3000 (Invitrogen) according the manufacturer’s instruc-
tions. Briefly, MSCs were seeded in 6-well plates with 
serum-free DMEM medium, and then subjected to the 
mixture of siRNA and Lipofectamine 3000 reagent. After 
incubation for 6  h, medium was changed and the cells 
were harvested for the further experiments.
Western blotting analysis
Briefly, total proteins from MSCs were separated on 
SDS–polyacrylamide gels, transferred onto nitrocellulose 
membranes, blocked and incubated with anti-Nrf2, anti-
Sirt3, anti-total FoxO3a, and phosphorylated-FoxO3a 
(p-FoxO3a, Ser253 and Ser318/321) antibodies (1:1000, 
Cell Signaling Technology) and anti-tubulin antibodies 
(1:10000, Abcam) overnight at 4  °C. Membranes were 
then washed 3 times and incubated with secondary anti-
bodies for 1 h at room temperature. The semi-quantita-
tive analysis (AlphaView Software 3.3, Cell Biosciences, 
Inc.) results were expressed as the optical volume densi-
ties (OD × mm2) normalized to tubulin.
MSC differentiation
For osteogenic differentiation, MSCs were cultured in 
osteogenic differentiation medium containing 10% FBS, 
0.2  mmol/L ascorbate, 10  mmol/L b-glycerolphosphate, 
0.1  mmol/L dexamethasone, 100  U/ml penicillin and 
100  mg/ml streptomycin (all from Cyagen, Guangzhou, 
China) at the confluence of 60–70%. Osteogenic medium 
was changed every 3  days. After induction for 21  days, 
cells were fixed by 4% formaldehyde, and then stained 
with Alizarin Red S to assess calcium deposits.
MSCs at 100% confluence were used for adipo-
genic differentiation. Cells were first cultured in adipo-
genic induction medium supplemented with 10% FBS, 
1  mmol/L dexamethasone, 100  mmol/L indomethacin, 
0.5  mmol/L methyisobutylxanthine, 10  mmol/L insu-
lin, 100 U/ml penicillin and 100 mg/ml streptomycin for 
3  days, followed by cultivating in maintenance medium 
consisting of 10% FBS, 5 mg/ml insulin, 100 U/ml peni-
cillin and 100 mg/ml streptomycin for 24 h. After 4 cycles 
of induction/maintenance exchange, MSCs were cultured 
in maintenance medium for 6  days and finally fixed by 
4% formaldehyde. Lipid droplets were examined using oil 
red O solution staining.
Colony forming unit (CFU) assay
To test the self-renewal capacity of CHBP-treated MSCs, 
CFU assay was conducted. In brief, MSCs were plated in 
10 cm dishes at a density of 50 cells/cm2 and cultured in 
normal complete medium in the presence or absence of 
10 nM CHBP for 14 days, with medium exchange every 
3 days. At the end of cultivation, cells were washed with 
PBS, fixed by 4% formaldehyde for 30  min and stained 
with 2% crystal violet for 10 min. Subsequently, cells were 
washed with PBS for 3 times and left drying. Colonies 
consisting of more than 50 cells were defined as CFUs 
and were counted.
Statistical analysis
All data are presented as mean ± standard deviation. Sta-
tistical analysis was performed using the Student’s t test 
or one-way ANOVA by SPSS 19.0 software (SPSS Inc., 
Armonk, NY, USA). P < 0.05 was recognized as statisti-
cally significant.
Results
CHBP preserved the viability of MSCs during starvation
To examine the possible protection of CHBP, cell viabil-
ity of nutrient-starved MSCs treated with different con-
centrations of CHBP (0, 0.1, 1, 10 nmol/L) was analyzed 
using CCK-8 assay. Figure 1a exhibited the dynamics of 
cell viability during starvation. Serum deprivation, just 
as expected, caused significant decrease of cell viability 
compared with normal control. CHBP were able to par-
tially alleviate the decrease of viability in a dose-depend-
ent manner, and the protective effect was observed for 
up to 72  h of starvation. We observed that starvation 
resulted in the detachment of cells, which usually rep-
resented cell death. Therefore, we further used Trypan 
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blue staining to determine loss of cell membrane integ-
rity and found that CHBP could obviously inhibit star-
vation-induced cell death (Fig. 1b). To exclude a possible 
protective effect of peptide molecule itself, a scrambled 
peptide was used and identified no detectable protec-
tion. To examine whether CHBP itself has an effect on 
the proliferation of MSCs, we subjected MSCs to CHBP 
at various concentrations in complete medium. As shown 
in Fig. 1c, CHBP had no detectable impact on the prolif-
eration of MSCs at the concentration used in the present 
study. Collectively, our data suggested that CHBP could 
preserve cell viability against starvation by alleviating cell 
death.
CHBP attenuated starvation‑induced apoptosis in MSCs
To further delineate the effect of CHBP in starvation-
induced cell death, apoptosis and necrosis was quali-
tatively analyzed using Annexin V/PI assay by flow 
cytometry. Annexin V−/PI− represents live cells; 
Annexin V+/PI− or Annexin V−/PI+ represents early 
or late apoptosis phase respectively; Annexin V+/PI+ 
reflects necrosis. As suggested in Figs. 2a, 3a, starvation 
induced significant apoptosis (Annexin V+) that exacer-
bated over time and CHBP, in contrast, markedly inhib-
ited apoptosis in a concentration dependent manner. 
The highest concentration (10  nmol/L) was therefore 
applied for the following experiments. The protective 
effect of CHBP was also confirmed using Hoechst stain-
ing. Nuclear condensation observed in starved MSCs was 
obviously prevented by CHBP treatment (Fig. 3b). Taken 
together, these results indicated that CHBP attenuated 
starvation-induced apoptosis in MSCs. 
CHBP improved mitochondrial dysfunction in response 
to serum deprivation
Mitochondria are the main energy-producing orga-
nelles within cells and also play a key role in regulating 
cell bioactivity. Previous studies have shown that serum 
deprivation could result in mitochondrial dysfunction, 
which acted as an important contributor to apoptosis 
[28–30]. Therefore, we explored whether CHBP were 
able to diminish mitochondrial stress. Mitochondria are 
the main source of intracellular ROS, which is an inevi-
table product of the respiratory chain during oxidative 
Fig. 1 CHBP preserved the viability of MSCs during starvation. a MSCs were seeded in 96-well plates at a density of 1 × 104 cells/well and subjected 
to starvation. CHBP was administered at indicated concentrations. Scrambled peptide was also used as a control. Cell viability was determined by 
CCK-8. b MSCs seeded in 6-well plates at 1 × 106 cells/well were incubated in serum-free medium for 24 h in the absence or presence of CHBP and 
harvested for Trypan blue staining. c Effect of CHBP on the proliferation of MSCs under normal conditions was measured by CCK-8. Experiments 
were performed in triplicate. Data are expressed as mean ± standard deviation. *P < 0.05, **P < 0.01, ***P < 0.001
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phosphorylation. Excessive ROS accumulate during 
pathological conditions and cause oxidative damage. 
Several studies indicated that ROS might serve as an ini-
tiator of the mitochondrial change [31, 32]. As shown in 
Fig. 4a, serum deprivation led to an obvious increase of 
ROS, which was significantly alleviated by CHBP. MMP 
is recognized as a marker of mitochondrial statement. 
Physiologically, JC-1 is prone to form aggregates that are 
fluorescent red depending on the polarization of MMP; 
in contrast, when MMP collapses, JC-1 disperses into 
Fig. 2 CHBP suppressed apoptosis induced by serum deprivation. MSCs were seeded in 6-well plates at a concentration of 1 × 106/well and incu-
bated in serum-free medium for indicated time. The protective effect of CHBP against apoptosis was evaluated by Annexin V/PI asaay and Hoechst 
33258 staining. a Annexin V/PI asaay was performed by flow cytometry. Annexin V−/PI− represents live cells; Annexin V+/PI− or Annexin V−/
PI+ represents early or late apoptosis phase respectively; Annexin V+/PI+ reflects necrosis. Fragmentation and condensation of the nucleus were 
recognized as the characteristics of apoptotic cells. Experiments were performed in triplicate. Data are expressed as mean ± standard deviation. 
*P < 0.05 compared with control. **P < 0.01 compared with control
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monomers that are fluorescent green. Our data sug-
gested that CHBP could help maintain a normal polar-
ized MMP (Fig.  4b). Mitochondrial injury damages the 
integrity of mitochondrial membrane and leads to the 
leakage of cytochrome c, a promoter of inner apopto-
sis pathway. Normally, as shown in Fig.  4c, cytochrome 
c labeled with FITC colocalized with MitoRed-stained 
mitochondria. Under starvation, green fluorescence dra-
matically increased, indicating a release of cytochrome c 
from mitochondria. Consistent with the ROS generation 
and MMP results, CHBP inhibited mitochondrial mem-
brane breakdown. However, CHBP did not prevented the 
decrease in starvation-associated mitochondrial mass 
(Fig. 4d).
Nrf2/Sirt3/FoxO3a pathway may involve in the protection 
of CHBP against serum deprivation
Previous studies have shown that erythropoietin could 
upregulate nuclear factor erythroid 2-related factor 2 
(Nrf2), which could further induce Sirt3 expression to 
exert protective effect. Therefore, we presumed that 
CHBP, as an erythropoietin deviant, might protect MSCs 
against starvation stress via Nrf2/Sirt3 related pathway. 
To confirm this hypothesis, we detect the expression of 
Nrf2, Sirt3, total FoxO3a, and p-FoxO3a by western blot. 
As shown in Fig.  5a, Nrf2 and Sirt3 were significantly 
upregulated by CHBP, while p-FoxO3a was suppressed. It 
is well accepted that FoxO3a plays a crucial role in mito-
chondrial protection and the phosphorylation of FoxO3a 
can prevent its activation [33]. To further determine the 
role of Sirt3/FoxO3a pathway in the effect of CHBP, Sirt3 
siRNA was used. Compared with negative control (NC) 
siRNA-treated group, Sirt3 siRNA increased the level of 
p-FoxO3a and thereby inhibited the activation of FoxO3a. 
The NC siRNA were prone to downregulate p-FoxO3a, 
which, however, did not reach the statistic significance 
(Fig.  5a). Furthermore, we repeated the apoptosis assay 
by flow cytometry using Sirt3 siRNA-treated MSCs. As 
indicated in Fig. 5b, Sirt3 knockdown partially abolished 
the protection of CHBP, indicating a certain role of sirt3 
in the protective effect of CHBP. Taken together, all these 
results suggested that Nrf2/Sirt3/FoxO3a pathway might 
participate in the protection of CHBP on MSCs against 
serum deprivation.
Fig. 3 CHBP suppressed apoptosis induced by serum deprivation. MSCs were seeded in 6-well plates at a concentration of 1 × 106/well and incu-
bated in serum-free medium for indicated time. The protective effect of CHBP against apoptosis was evaluated by Annexin V/PI asaay and Hoechst 
33258 staining. a Quantification analysis of flow cytometry results was performed and demonstrated. b Hoechst 33258 staining was observed 
under fluorescence microscopy at ×100 magnification. Fragmentation and condensation of the nucleus were recognized as the characteristics 
of apoptotic cells. Experiments were performed in triplicate. Data are expressed as mean ± standard deviation. *P < 0.05 compared with control. 
**P < 0.01 compared with control
(See figure on next page.) 
Fig. 4 CHBP prevented mitochondrial dysfunction. MSCs were seeded in 6-well plates at a concentration of 1 × 106/well and incubated in serum-
free medium for 24 h with or without 10 nmol/L CHBP. MSCs cultured in complete medium were used as control. a To detect of mitochondria-
derived ROS, cells were incubated with MitoSOX reagent (2.5 mmol/L) for 30 min and analyzed by flow cytometry. b To measure mitochondrial 
membrane potential, cells were incubated with JC-1 reagent (5 mg/mL) for 30 min and analyzed by flow cytometry. c Cytochrome c was labeled 
by FITC and mitochondria were stained by MitoRed (50 nmol/L). Cells were observed by fluorescence microscopy under ×200 magnification. d 
For detection of mitochondrial mass, cells were incubated with MitoRed (50 nmol/L) for 30 min and analyzed by flow cytometry. Experiments were 
performed in triplicate. Data are expressed as mean ± standard deviation. *P < 0.05, **P < 0.01
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Fig. 5 Nrf2/Sirt3/FoxO3a pathway participated in the protective mechanism of CHBP against starvation. a MSCs were treated with siRNA targeting 
Sirt3 and then subjected to starvation with CHBP (10 nmol/L). Total protein was prepared from cultured cells. Expressions of Nrf2, Sirt3, total FoxO3a 
and p-FoxO3a were analyzed by western blotting. b Sirt3 siRNA treated MSCs were subjected to serum deprivation and apoptosis was detected by 
Annexin V/PI asaay. Experiments were performed in triplicate. Data are expressed as mean ± standard deviation. *P < 0.05, **P < 0.01
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MSCs pretreated with CHBP were more resistant 
to starvation
Pharmacological preconditioning is a well-accepted 
strategy to improve poor survival of transplanted cells. 
To investigate the potential protection of CHBP in a 
pretreatment manner, MSCs were pretreated with CHBP 
for 24 h and then subjected to serum-free medium. The 
results demonstrated that preconditioning of CHBP 
could also significantly inhibit apoptotic cell death 
in MSCs during serum deprivation (Fig.  6a, b). The 
Fig. 6 CHBP preconditioning rendered MSCs more resistant to starvation. a MSCs were preconditioned with CHBP at a concentration of 10 nmol/L 
and then subjected to serum starvation. Apoptosis was detected by Annexin V/PI asaay. b Quantification analysis of flow cytometry results was 
performed and demonstrated. Experiments were performed in triplicate. Data are expressed as mean ± standard deviation
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protective effect was observed for up to 48  h of starva-
tion, although the decrease of apoptosis at 48 h did not 
reach a statistical significance (P = 0.054). However, pre-
conditioning MSCs with CHBP for 24 h failed to improve 
the viability at 72 h (data not shown).
CHBP exerted little effects on the differential 
and self‑renewal capacity of MSCs
Multipotential differentiation and self-renewal capaci-
ties are hallmarks to define a stem cell. MSCs, as adult 
stem cells, are characterized by their differentiations into 
osteoblasts and adipocytes. To test whether treatment of 
CHBP could affect these biological activities, differentia-
tion and CFU assay were performed. As shown in Fig. 7a, 
b, preconditioning MSCs with CHBP at 10  nmol/L in 
normal medium for 3 days has no significant impact on 
the differential and self-renewal capability.
Discussion
In the past decade, there has been considerable interest 
in the exploration of MSCs as cell-based treatment for 
various diseases. However, poor survival of adaptively 
transferred MSCs limits their clinical therapeutic poten-
tial, which to a great extent is due to the nutrient star-
vation. Therefore, it is of vital importance to discover 
regimens that improve the viability of starved MSCs. This 
study aims to determine whether the organ-protective 
peptide CHBP can rescue MSCs that were subjected to 
serum deprivation. Serum deprivation is a widely used 
model of starvation that could initiate the intrinsic apop-
totic pathway [34]. In the present study, we confirmed 
that serum deprivation could result in apoptosis and 
exacerbate cell death as starvation time increased. It is 
demonstrated that CHBP could limit apoptosis of MSCs 
in a concentration-dependent manner. To detect whether 
this protection is a by-product effect of peptide mol-
ecule itself, a scrambled peptide is used as a control. No 
detectable protection was recognized for the scrambled 
peptide. Although erythropoietin and its deviants have 
been shown cytoprotection in the background of starva-
tion, the underlying mechanisms are not fully elucidated 
[35–38].
Mitochondria, in addition to the well-known energy-
producing function, also serve as a crucial mediator of 
cell injury and death [39, 40]. Physiologically, the homeo-
stasis of mitochondria is finely orchestrated by a complex 
network consisting of intracellular proteins and micro-
environments. Upon severe stresses, such homeostasis 
can be dramatically damaged, leading to mitochondrial 
dysfunction and consequent cell death. Consistent with 
previous studies [28–30, 41], out data showed that serum 
deprivation induced mitochondrial dysfunction, result-
ing in increased ROS, impaired MMP and release of 
cytochrome c. ROS is an inevitable product of the respir-
atory chain during oxidative phosphorylation. Pathologi-
cal stimuli such as nutrient starvation cause a functional 
Fig. 7 CHBP had no impact on the differential and self-renewal capacity of MSCs. MSCs were incubated with CHBP at a concentration of 10 nmol/L 
for 3 days and then harvested for a adipogenic differentiation, b osteogenic differentiation, and c Colony forming unit assay. Photographs are repre-
sentatives of three independent experiments. Data are expressed as mean ± standard deviation
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disruption of mitochondria and consequently result in 
excessive ROS generation, which induced undesirable 
oxidative damage to DNA, proteins, and organelles and 
even lead to cell death [42–44]. Simultaneously, as the 
main source of ROS, mitochondria itself acts as a pref-
erable target for the deleterious effect of ROS. Oxidative 
stress in turn deteriorates mitochondrial dysfunction and 
amplifies mitochondrial collapse in a positive feedback 
loop. In contrast, CHBP could alleviate mitochondrial 
stress by diminishing oxidative injury of ROS, restor-
ing MMP and maintaining mitochondrial membrane 
integrity.
Our results further indicated that antioxidant Nrf2/
Sirt3/FoxO3a axis might involve in the protection of 
CHBP against serum deprivation. Nrf2, also known as 
GA-binding protein, is a transcription factor belonging 
to E26 transformation-specific factor family [45]. Nrf2 
interacts with PGC-1α to regulate key functional sign-
aling within mitochondria and actives the expression of 
many cytoprotective proteins including Sirt3 [46–48]. 
Previous studies have shown that erythropoietin could 
induce Nrf2 expression [49–51]. Accordingly, we found 
that CHBP was also able to upregulate Nrf2 as well as 
Sirt3 in the background of starvation. Very recently, 
increasing evidence demonstrated that Sirt3/FoxO3a 
pathway served as an important contributor to the mito-
chondrial protection in response to cellular stresses 
[52–54]. Sirt3 is a mitochondrial deacetylase involving 
in several important metabolic processes [55, 56]. The 
Sirt3-mediated deacetylation of FoxO3a further reduces 
FoxO3a phosphorylation [53]. The function of FoxO3a 
is critically modulated by phosphorylation: phosphoryl-
ated FoxO3a retains in the cytoplasm and keeps func-
tionally inactive; in contrast, dephosphorylation leads to 
its transfer to the nucleus to activate target genes [33]. 
Our results provided direct evidence for the activation of 
FoxO3a by Sirt3 and revealed that Sirt3 knockdown par-
tially abolished the protection of CHBP.
Scientific community has paid much attention to 
improve the viability of MSCs in response to nutrient 
deprivation. Treatment of various reagents is considered 
as a feasible procedure to protect MSCs from starvation. 
Among them, there are hormone, endogenous substance, 
clinically approved drug, peptide and energy resource 
ATP [57–62]. Neuropeptide substance P (SP) is a pep-
tide containing 11 amino acids and has been suggested to 
inhibit starvation-induced apoptosis by enhancing Wnt 
pathway [60]. Moreover, another study shows that the 
glucose-dependent insulinotropic peptide (GIP) exerts an 
anti-apoptotic function by regulating adenylate cyclase 
[58]. These studies suggested that peptides serve as effec-
tive adjuvant agents for improving MSC-based therapies. 
As a peptide, CHBP is relatively low-cost, feasible for 
large-scale production and stable under various patho-
physiologic conditions. In addition, no obvious effect of 
CHBP is observed upon the osteogenic and adipogenic 
differentiation, as well as the self-renewal capacity that 
are crucial hallmarks of MSCs. In this regard, CHBP 
shows a promising prospect in the clinical practice.
Conclusions
In conclusion, the present study demonstrates the effi-
cient protection of CHBP upon MSCs against star-
vation-induced apoptosis and unveils the underlying 
mechanism of this protective effect. These results pro-
vide a better understanding of the multiple pharmaco-
logic functions of CHBP and indicate a possible role of 
CHBP in regulating nutrient-associated biological pro-
cesses. Our study suggests that CHBP holds great prom-
ise for sustaining cell survival under nutrient-deprived 
conditions and improving the therapeutic effective-
ness of MSC-based treatment. However, the efficacy of 
CHBP-treated MSCs needs further confirmation in vivo 
in the future.
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